CRDF
Cardiff Oncology, Inc.
Next earnings Jul 27, 2026 (after close) · consensus $-0.16 EPS, $72.1K rev
Last earnings +2.4% on 2026-05-14
$1.25
▲ +3.31%$1.25▼ -60.44%
over 1Y
L $1.18EODHDH $4.45
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.3%
1W-3.8%
1M-30.9%
3M-19.4%
YTD-53.0%
1Y-60.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.36x); but revenue fell -13.2% YoY.
Revenue (FY2025) $593K · FY2025
Cardiff Oncology, Inc. shows $593K in FY2025 revenue (-13.2% YoY), a -7732.0% net margin, and -101.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $359K | $386K | $488K | $683K | $593K |
| Gross profit | — | — | — | — | — |
| Operating income | -$28.9M | -$39.9M | -$45.4M | -$48.7M | -$49.0M |
| Net income | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| Diluted EPS | -$0.73 | -$0.89 | -$0.93 | -$0.95 | -$0.69 |
| Net margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$68.0M
EV / EBITDA—
EV / Sales114.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-53.7%
FCF yield-44.4%
Quality & risk
ROIC (est.)-85.2%
Free cash flow-$38.0M
Total debt—
Net cash$17.5M
Altman Z-Score-8.37 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗8-KPeriod ending 2026-06-112026-06-11open ↗8-KPeriod ending 2026-06-032026-06-03open ↗8-KPeriod ending 2026-05-272026-05-29open ↗8-KPeriod ending 2026-05-192026-05-19open ↗8-KPeriod ending 2026-05-142026-05-14open ↗
Frequently asked
- Is Cardiff Oncology, Inc. (CRDF) a buy?
- CRDF currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.36x); but revenue fell -13.2% YoY.
- What is Cardiff Oncology, Inc.'s quality score?
- CRDF scores 32.450980392156865/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001213037, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 6:13:17 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.